Testing Whether Avoiding the Hippocampus in Addition to Memantine During Whole-Brain Radiation Therapy Better Prevents Cognitive Side Effects in People With Brain Metastases


Currently Unavailable for Patients

About This Study

This study closed to patient enrollment on April 24, 2020.

The hippocampus is a brain structure (see picture) that is important for memory. This study compared the effects of avoiding the hippocampus during whole-brain radiation therapy plus memantine to the usual wholebrain radiation therapy plus memantine. Memantine is an FDA-approved drug for patients with dementia and is commonly used off-label (meaning for other diseases besides dementia) for patients receiving whole-brain radiation therapy for patients with brain cancer. This study further explored whether the hippocampal avoidance technique will prevent cognitive (such as thinking, memory, use of words/language) side effects

Read the Study Results Summary from this Trial


 

About NRG Oncology

At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trial's Network.